Fed Circ revives claims in St Jude’s catheter patent suit
12-04-2022
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16-02-2021
Russian drugmakers bypass Gilead to unveil COVID-19 generic
04-02-2021
18-11-2021
Sundry Photography / Shutterstock.com
The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead , BMS, Kite Pharma, Juno Therapeutics, big pharma